Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER vs AKOVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Treatment of clinically important hypotension occurring in the setting of anesthesia
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
5 mg intravenously once daily.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Terminal elimination half-life: 3-4 hours, prolonged in renal impairment (up to 8-12 hours in severe CKD).
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Hepatic metabolism via oxidative deamination and demethylation; primarily metabolized by CYP2D6; some metabolites are active.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites and unchanged drug.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
85% bound to albumin and alpha-1-acid glycoprotein.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Vd: 1.5-2.0 L/kg, indicating extensive tissue distribution.
100% intravenous; not administered by other routes.
Oral: 75% (first-pass metabolism minimal).
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
Not required as AKOVAZ is not renally excreted.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
No dose adjustment needed based on Child-Pugh classification.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
0.1 mg/kg intravenously once daily, maximum 5 mg.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
No specific dose adjustment required; use caution due to potential age-related decreased renal function.
Not applicable; no FDA boxed warning exists for this product.
None
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hypertension: May cause severe hypertension, including hypertensive crisis, especially with concurrent MAOIs or other vasopressors.,Arrhythmias: May induce ventricular arrhythmias, especially in patients with underlying cardiac disease.,Risk of stroke: Hypertensive effects may increase risk of intracranial hemorrhage.,Tachyphylaxis: Repeated use may lead to decreased response.,Extravasation: Risk of tissue necrosis if extravasation occurs.,Use caution in patients with hyperthyroidism, pheochromocytoma, or diabetes.
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
Hypersensitivity to ephedrine or other sympathomimetics,Concurrent use with MAOIs or within 14 days after discontinuation,Angle-closure glaucoma,Severe hypertension or cardiovascular disease
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
No known food interactions. This drug is administered intravenously, so dietary restrictions are not applicable. However, oral intake should not interfere with therapy.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Akovaz (ephedrine sulfate) is classified as FDA Pregnancy Category C. In first trimester, there is insufficient human data; animal studies show teratogenic effects at high doses. In second and third trimesters, use may cause fetal tachycardia, reduced uteroplacental blood flow, and potential for neonatal withdrawal or toxicity. Risk of maternal hypertension and decreased uterine perfusion outweighs benefits unless clearly indicated.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
Ephedrine is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 2.5-3.0. Peak milk concentration occurs 1-2 hours after dose. Potential for infant stimulation, irritability, and sleep disturbances. Use with caution; monitor infant for adverse effects. Avoid in lactation if possible or use lowest effective dose for shortest duration.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
Pharmacokinetic changes in pregnancy (increased plasma volume, altered binding proteins) may reduce peak concentrations of ephedrine. However, no specific dose adjustment recommendations are established for Akovaz in pregnancy. Use the lowest effective dose to achieve desired effect (typically 5-10 mg IV for hypotension). Monitor clinical response closely; dose titration may be needed due to altered sensitivity of adrenergic receptors in pregnancy. Avoid prolonged use.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
AKOVAZ (ceftolozane/tazobactam) is a cephalosporin/beta-lactamase inhibitor combination used primarily for hospital-acquired pneumonia and complicated urinary tract infections. Monitor renal function closely; dose adjustment required for Cr Cl < 50 m L/min. Administer intravenously over 1 hour. Observe for hypersensitivity reactions, including anaphylaxis, particularly in penicillin-allergic patients. Consider cross-reactivity with other beta-lactams. Collect cultures before initiation.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
This medication is given intravenously to treat serious bacterial infections.,Report any signs of allergic reaction immediately: rash, itching, difficulty breathing, swelling of face or throat.,Diarrhea may occur; contact your provider if it is severe, watery, or bloody.,Do not skip doses; complete the full course of treatment even if you feel better.,Tell your healthcare provider about all medications, especially blood thinners (e.g., warfarin) and other antibiotics.,Kidney function will be monitored with blood tests; drink adequate fluids unless told otherwise.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER vs AKOVAZ, answered by our medical review team.
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. AKOVAZ is a Topical Antibiotic that works by Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER and AKOVAZ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. The standard adult dose of AKOVAZ is: 5 mg intravenously once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER and AKOVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. AKOVAZ is classified as Category C. Akovaz (ephedrine sulfate) is classified as FDA Pregnancy Category C. In first trimester, there is insufficient human data; animal studies show teratogenic effects at high doses. I. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.